Thermo Fisher completed the acquisition of PeproTech for $1.85bn.

Thermo Fisher, a manufacturer of scientific instruments, consumables, and chemicals, completed the acquisition of PeproTech, a developer and manufacturer of recombinant proteins, for $1.85bn. "PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering. In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our mission to enable our customers to make the world healthier, cleaner and safer," Marc N. Casper, Thermo Fisher Chairman, President and CEO.